Everything we've seen

1. ·Nov 15, 11:32 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

2. ·Nov 15, 11:18 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

3. ·Nov 15, 11:03 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

4. ·Nov 15, 10:48 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

5. ·Nov 15, 10:33 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

6. ·Nov 15, 10:17 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

7. ·Nov 15, 10:03 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

8. ·Nov 15, 9:47 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

9. ·Nov 15, 9:33 AMstreamnews

   Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

   ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

10. ·Nov 15, 9:18 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

11. ·Nov 15, 9:03 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

12. ·Nov 15, 8:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

13. ·Nov 15, 8:33 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

14. ·Nov 15, 8:17 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

15. ·Nov 15, 8:03 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

16. ·Nov 15, 7:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

17. ·Nov 15, 7:32 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

18. ·Nov 15, 7:17 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

19. ·Nov 15, 7:03 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

20. ·Nov 15, 6:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

21. ·Nov 15, 6:33 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

22. ·Nov 15, 6:17 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

23. ·Nov 15, 6:03 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

24. ·Nov 15, 5:47 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

25. ·Nov 15, 5:33 AMstreamnews

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

26. ❖Nov 13, 8:20 PMnewsvia finnhub

    Is There Any Reason To Invest In Edwards Lifesciences Stock?

    For questions about this article or underlying research, email help@trefis.com.

27. ❖Nov 13, 10:15 AMnewsvia finnhub

    Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

    ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.

28. ?Nov 12, 2:45 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down ~1.80% with only 60 minutes remaining until the forced close. The move is meaningful but not extreme. Key factors weighing against continuation: (1) With only 60 minutes left, there is limited runway for momentum to extend further — late-session mean reversion is common for moves of this magnitude without a clear catalyst. (2) The macro context (T10YIE at 1.7σ below trend, implying lower real yields) is modestly supportive of long-duration healthcare/device names, creating a mild headwind against further downside. (3) The headline 'Is Abbott Laboratories (ABT) Undervalued On New Device And Test Launches?' suggests some buy-side interest and potential dip-buyers entering the name, which could arrest or reverse the decline. (4) No clear negative catalyst is visible in the news flow — the sell-off lacks an obvious fundamental driver, which increases the probability this is technical/flow-driven and subject to fade. (5) The microfluidics report mentioning ABT is sector-neutral/positive. On balance, the absence of a negative catalyst, supportive macro rate environment, and limited time remaining all argue that this down move is more likely to fade or stabilize than to continue lower into the close.

29. !Nov 12, 2:45 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    ABT is down ~1.80% with only 60 minutes remaining until the forced close. The move is meaningful but not extreme. Key factors weighing against continuation: (1) With only 60 minutes left, there is limited runway for momentum to extend further — late-session mean reversion is common for moves of this magnitude without a clear catalyst. (2) The macro context (T10YIE at 1.7σ below trend, implying lower real yields) is modestly supportive of long-duration healthcare/device names, creating a mild headwind against further downside. (3) The headline 'Is Abbott Laboratories (ABT) Undervalued On New Device And Test Launches?' suggests some buy-side interest and potential dip-buyers entering the name, which could arrest or reverse the decline. (4) No clear negative catalyst is visible in the news flow — the sell-off lacks an obvious fundamental driver, which increases the probability this is technical/flow-driven and subject to fade. (5) The microfluidics report mentioning ABT is sector-neutral/positive. On balance, the absence of a negative catalyst, supportive macro rate environment, and limited time remaining all argue that this down move is more likely to fade or stabilize than to continue lower into the close.

30. ?Nov 12, 1:30 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 1.57% intraday, a moderate but not dramatic move. No clear catalysts are driving the sell-off — the headlines are largely neutral to mildly positive (undervaluation article, sector report, competitor news). With 135 minutes remaining there is meaningful time left in the session, but the macro context is notable: T10YIE at 1.7σ below trend implies compressed inflation expectations, which is actually supportive for long-duration sensitive sectors like medtech/healthcare, potentially creating a headwind for further downside. The absence of a negative catalyst driving the move raises the possibility this is rotation or sector-level selling that could stabilize or reverse. The magnitude (1.57%) is not large enough to signal strong conviction selling. Balancing modest downside momentum against a supportive macro backdrop and no confirming negative news, the probability of continuation just falls short of the 0.5 threshold to trigger a position.

31. !Nov 12, 1:30 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    ABT is down 1.57% intraday, a moderate but not dramatic move. No clear catalysts are driving the sell-off — the headlines are largely neutral to mildly positive (undervaluation article, sector report, competitor news). With 135 minutes remaining there is meaningful time left in the session, but the macro context is notable: T10YIE at 1.7σ below trend implies compressed inflation expectations, which is actually supportive for long-duration sensitive sectors like medtech/healthcare, potentially creating a headwind for further downside. The absence of a negative catalyst driving the move raises the possibility this is rotation or sector-level selling that could stabilize or reverse. The magnitude (1.57%) is not large enough to signal strong conviction selling. Balancing modest downside momentum against a supportive macro backdrop and no confirming negative news, the probability of continuation just falls short of the 0.5 threshold to trigger a position.

32. ❖Nov 12, 11:21 AMnewsvia finnhub

    Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown

    BSX bets on WATCHMAN growth through clinical trials and physician outreach, even as slowing demand and rising competition cloud its outlook.

33. ❖Nov 12, 9:57 AMnewsvia finnhub

    Microfluidic Device Systems - Global Strategic Business Report 2026: Capitalize on 8.7% CAGR to $11.1 Billion by 2032 | Abbott, Danaher, Bio-Rad, and Siemens Healthineers Shape the Competition

    Target point-of-care diagnostics, precision medicine and drug discovery; automation, miniaturization and low reagent use can cut costs, speed workflows and support scalable growthDublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Microfluidic Device Systems - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global microfluidic device systems market was valued at US$6.2 billion in 2025 and is projected to reach US$11.1 billion by 2032, expanding at a compoun

34. ❖Nov 12, 9:10 AMnewsvia finnhub

    Is Abbott Laboratories (ABT) Undervalued On New Device And Test Launches?

    Abbott Laboratories (ABT) has been back in focus after two health focused product milestones. The firm secured FDA and CE approvals for its UltiSynq defibrillation lead and launched the Panbio COVID-19/Flu A&B Self-Test in Canada. Despite a stream of new device approvals and test launches, Abbott Laboratories’ share price has slipped about 12% year to date. A 7.34% 1 month share price return suggests short term momentum is picking up, even as the 1 year total shareholder return is still down...

35. ❖Nov 12, 8:30 AMnewsvia finnhub

    Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump

    SAN DIEGO, November 12, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval of a license amendment for the t:slim X2™ insulin pump with Control-IQ+™ automated insulin delivery (AID) technology. This approval adds compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor and expands the t:slim X2 system’s indications for use to people with type 1 diabetes during pregnancy and to adults with

36. ❖Nov 12, 7:56 AMnewsvia finnhub

    Abbott vs. Medtronic: Which Dividend Stock Pays You More in 10 Years?

    Key TakeawaysMedtronic finished splitting off its MiniMed diabetes business on Oct. 15, and Abbott plans to spin off its Nutrition business by the end of 2027.

37. ❖Nov 12, 5:54 AMnewsvia finnhub

    ISRG Agrees to $450M Settlement: What Does It Mean for Investors?

    Intuitive Surgical's $450 million settlement weighs on Q3 earnings, but strong revenues and procedure growth highlight underlying momentum.

38. ❖Nov 11, 10:23 PMnewsvia finnhub

    Warren Buffett Says His Favorite Holding Period Is Forever. A Secretary Who Paid $180 for 3 Shares in 1935 and Never Sold Died Worth $7 Million. Here’s What Her Rule Does for $600,000 in One Stock Today

    Warren Buffett's favorite holding period is forever. Grace Groner, a secretary at Abbott, paid $180 for three shares in 1935, reinvested every dividend, never sold, and left Lake Forest College $7 million when she died at 100 in 2010. Here is what the splits did, what the dividends did, what the S&P 500 would have paid, the fall she sat through at 93, and what her rule does for a retired couple holding $600,000 of one old stock today.

39. ❖Nov 11, 9:45 PMnewsvia finnhub

    Medtronic Kept Growing When All Eyes Were On AI, Time To Give This Growth Justice

    Medtronic expands its heart-rhythm business with Affera and PulseSelect, driving material revenue growth. Find out why MDT stock is a buy.

40. ❖Nov 11, 4:17 PMnewsvia finnhub

    Is DexCom Stock Cheaper Now That Its Multiple Has Fallen?

    For questions about this article or underlying research, email help@trefis.com.

41. ❖Nov 11, 3:21 PMnewsvia finnhub

    Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

    Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

42. ❖Nov 11, 10:47 AMnewsvia finnhub

    Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

    ABT's UltiSynq lead combines conduction system pacing and defibrillation, with strong clinical trial results supporting its potential to expand the company's cardiac rhythm management portfolio.

43. ❖Nov 11, 10:17 AMnewsvia finnhub

    3 Legacy Health Care Dividend Stocks That Never Go Out of Style

    Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by a single cent.

44. ❖Nov 11, 9:13 AMnewsvia finnhub

    Molecular Cytogenetics - Global Strategic Business Report: Capitalize on 8.8% CAGR to US$3.5 Billion by 2030; Outmaneuver Abbott, Agilent, Bio-Rad, Illumina and Roche Amid Tariff Shifts

    Capitalize on personalized medicine, advanced genetic testing and cancer diagnostics with tariff-aware sourcing, regional analysis and competitive insights.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Molecular Cytogenetics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global molecular cytogenetics market was valued at US$2.1 billion in 2024 and is projected to reach US$3.5 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.8% fro

45. ❖Nov 10, 9:20 AMnewsvia finnhub

    Gene Amplification Technologies - Global Strategic Business Report: Capture $4.4B in New Revenue by 2030 as Abbott, Bio-Rad, bioMerieux, Cepheid and Becton Dickinson Battle for Share

    Target personalized medicine, diagnostics and pharma R&D with PCR, NGS and CRISPR innovation; tariff, regional and competitive insights reveal revenue opportunities.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Gene Amplification Technologies - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global gene amplification technologies market, valued at US$5.7 billion in 2024, is projected to reach US$10.1 billion by 2030. This represents a compound annual growt

46. ❖Nov 10, 6:08 AMnewsvia finnhub

    New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season

    As respiratory viruses begin circulating across Canada, many families are left wondering what to do when illness strikes at home. To help provide greater clarity, Abbott (NYSE: ABT) today announced availability of its Panbio™ COVID-19/Flu A&B Self-Test, which can identify COVID-19, Influenza A and Influenza B from a single nasal swab in approximately 15 minutes.

47. ❖Nov 10, 3:59 AMnewsvia finnhub

    What Are Wall Street Analysts' Target Price for Abbott Stock?

    While Abbott has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

48. ❖Nov 7, 3:12 PMnewsvia finnhub

    Does FDA Device Approval Change The Bull Case For Abbott (ABT)?

    Abbott Laboratories reported a flurry of cardiology and oncology product updates over late October and early November 2026, including FDA approval for the Amplatzer Paraclose PVL Occluder, strong study results for the investigational Amulet 360 and SonicForce coronary IVL system, and commercial launch of the next-generation Oncodetect MRD test. These device and diagnostic milestones point to Abbott Laboratories pushing deeper into higher complexity procedures and cancer monitoring, which can...

49. ❖Nov 7, 8:47 AMnewsvia finnhub

    3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years

    Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year. Only one has a streak long enough to outlast most investors' careers, and its latest raise tells a surprising story.

50. ❖Nov 7, 7:49 AMnewsvia finnhub

    What Is Behind The Move In DexCom Stock?

    For questions about this article or underlying research, email help@trefis.com.

51. ❖Nov 7, 5:06 AMnewsvia finnhub

    What Could Go Wrong At Boston Scientific From Here?

    For questions about this article or underlying research, email help@trefis.com.

52. ❖Nov 7, 12:35 AMnewsvia finnhub

    69 Dividend Champions Ranked By Quality Scores (November 2026)

    Explore 69 Dividend Champions ranked by quality, safety, and value.

53. ?Nov 6, 2:30 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 2.69% with 75 minutes remaining — a meaningful move with limited time to extend further. No clear catalysts in the headlines; the biohacking/wearable market report is a broadly positive mention but not a price-moving event, and the NAD headline is unrelated to ABT. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to Abbott as a healthcare/medtech company, so no macro tailwind or headwind amplifying the move. With 75 minutes left, the move has already been in progress and there is meaningful risk of late-session mean reversion as short-sellers cover and value buyers step in near a -2.69% intraday level. The absence of a clear negative catalyst (earnings miss, FDA action, guidance cut) makes sustained continuation into the close less likely — this looks more like a large seller or sector rotation flush that may be largely exhausted. Probability tips just below the 0.5 threshold, favoring a fade or stabilization rather than continuation.

54. !Nov 6, 2:30 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    ABT is down 2.69% with 75 minutes remaining — a meaningful move with limited time to extend further. No clear catalysts in the headlines; the biohacking/wearable market report is a broadly positive mention but not a price-moving event, and the NAD headline is unrelated to ABT. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to Abbott as a healthcare/medtech company, so no macro tailwind or headwind amplifying the move. With 75 minutes left, the move has already been in progress and there is meaningful risk of late-session mean reversion as short-sellers cover and value buyers step in near a -2.69% intraday level. The absence of a clear negative catalyst (earnings miss, FDA action, guidance cut) makes sustained continuation into the close less likely — this looks more like a large seller or sector rotation flush that may be largely exhausted. Probability tips just below the 0.5 threshold, favoring a fade or stabilization rather than continuation.

55. ❖Nov 6, 1:30 PMnewsvia finnhub

    Dividend Champion, Contender, And Challenger Highlights: Week of November 8

    Get the latest dividend activity for Dividend Champions, Contenders, and Challengers. Read this week's list here.

56. ❖Nov 6, 10:00 AMnewsvia finnhub

    National Advertising Division to Refer Kendal to Government Agencies and Advertising Platforms for Electing Not to Participate in Compliance Inquiry

    Following a compliance inquiry stemming from a prior decision, BBB National Programs’ National Advertising Division will refer Kendal Nutricare Limited to appropriate government and state agencies and advertising platforms for review and possible enforcement action after the company elected not to participate in the compliance inquiry.New York, NY, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Following a compliance inquiry stemming from a prior decision, BBB National Programs’ National Advertising Division

57. ❖Nov 6, 9:14 AMnewsvia finnhub

    Global Biohacking Wearable and Consumer Longevity Device Market Report 2026 | Capitalize on AI Biometrics as Apple, Samsung, Abbott, and Oura Drive Market to $45.03 Billion by 2030

    Apple, Samsung, Huawei, Abbott and ASUS. Profiled: competitors, regional shares, segments, trends and opportunities in biohacking wearables and longevity devices.Dublin, Nov. 06, 2026 (GLOBE NEWSWIRE) -- "Biohacking Wearable and Consumer Longevity Device Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global biohacking wearable and consumer longevity device market is experiencing rapid growth as consumers increasingly adopt connected technologies for preventiv

58. ❖Nov 5, 4:05 PMnewsvia finnhub

    Tandem Diabetes Care Announces Third Quarter 2026 Financial Results

    SAN DIEGO, November 05, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026.

59. ❖Nov 5, 3:05 PMnewsvia finnhub

    3 Dividend Kings to Buy in November and Never Sell

    These are arguably among the most reliable dividend payers.

60. ?Nov 5, 1:31 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down ~2% today with 135 minutes remaining — enough time for further directional movement. The lone headline is a generic market research report on bioelectronic medicine that is not a negative catalyst and does not explain the move. The macro context (DFF elevated ~2.1σ above trend at 3.88%) is modestly hawkish and somewhat negative for growth/medtech valuations, providing a mild tailwind for further weakness. However, with no clear catalytic driver identified for the initial selloff, there is elevated risk this is an overreaction subject to mean reversion, particularly in a large-cap, relatively defensive name like ABT. The move is at the lower end of the 2-5% 'conviction flow' threshold (~2%), which tempers momentum confidence. With no strong reversal signal observed either, this sits squarely at the borderline. Applying the system's bias toward action at uncertainty, I assign 0.5 continuation probability to the downside — a marginal hold-down read with limited edge but bounded risk given the tight stop structure.

61. !Nov 5, 1:31 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    ABT is down ~2% today with 135 minutes remaining — enough time for further directional movement. The lone headline is a generic market research report on bioelectronic medicine that is not a negative catalyst and does not explain the move. The macro context (DFF elevated ~2.1σ above trend at 3.88%) is modestly hawkish and somewhat negative for growth/medtech valuations, providing a mild tailwind for further weakness. However, with no clear catalytic driver identified for the initial selloff, there is elevated risk this is an overreaction subject to mean reversion, particularly in a large-cap, relatively defensive name like ABT. The move is at the lower end of the 2-5% 'conviction flow' threshold (~2%), which tempers momentum confidence. With no strong reversal signal observed either, this sits squarely at the borderline. Applying the system's bias toward action at uncertainty, I assign 0.5 continuation probability to the downside — a marginal hold-down read with limited edge but bounded risk given the tight stop structure.

62. ❖Nov 5, 10:39 AMnewsvia finnhub

    Bioelectronic Medicine and Neural Interface Devices Global Market Report 2026 | Capture 20.9% CAGR as Abbott, Boston Scientific, Neuralink and Science Advance Closed-Loop Systems

    Profiles Abbott Laboratories, Boston Scientific, BrainsWay, Cala Health and CorTec, covering their bioelectronic medicine and neural interface devices.Dublin, Nov. 05, 2026 (GLOBE NEWSWIRE) -- "Bioelectronic Medicine And Neural Interface Devices Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Bioelectronic Medicine and Neural Interface Devices Market to Reach $5.25 Billion by 2030 The global bioelectronic medicine and neural interface devices market is experiencin

63. ❖Nov 5, 7:32 AMnewsvia finnhub

    Are You Overpaying For Abbott Stock Versus Its Rivals?

    For questions about this article or underlying research, email help@trefis.com.

64. ❖Nov 4, 1:03 PMnewsvia finnhub

    These 12 stocks are good bets to beat the 10-year Treasury over the next decade

    Investment newsletters’ favorite Dividend Aristocrat stocks

65. ❖Nov 4, 10:16 AMnewsvia finnhub

    Cell Counting - Global Strategic Business Report 2026: Capitalize on US$6 Billion Growth by 2032 as Abbott, Becton Dickinson, Bio-Rad, Danaher, and Sysmex Drive Automation

    Capitalize on demand for automated, AI-enabled cell counting across drug discovery, personalized medicine, diagnostics and biopharma quality control.Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Cell Counting - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell counting market was valued at US$10.8 billion in 2025 and is projected to reach US$16.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 6.5%. Market growth is sup

66. ❖Nov 4, 10:09 AMnewsvia finnhub

    Abbott Laboratories (ABT) Posted Positive Trial Results For Two Heart Devices

    Abbott Laboratories (NYSE:ABT) reported positive one year VERITAS trial outcomes for its Amulet 360 device in atrial fibrillation patients. The Amulet 360 Left Atrial Appendage Occluder showed high safety and efficacy for stroke risk reduction in the VERITAS study. TECTONIC trial data indicated strong performance of Abbott's SonicForce Coronary IVL System in treating severe coronary artery calcification. The VERITAS and TECTONIC results for Amulet 360 and SonicForce fit into a broader...

67. ✓Nov 4, 9:36 AMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — pyramid

    Pyramid add-on fired at +10.59% unrealized. Added 7 sh @ $114.45 ($801.15). Position now 21 sh @ weighted avg $107.14.

68. ❖Nov 4, 8:55 AMnewsvia finnhub

    BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak

    Boston Scientific's cyber disruption cuts Q3 growth and earnings, forcing lower 2026 guidance as management sees 2027 as the cycle's trough.

69. ❖Nov 4, 8:41 AMnewsvia finnhub

    Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer

    DALLAS & OSS, Netherlands, November 04, 2026--Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 year

70. ❖Nov 4, 4:43 AMnewsvia finnhub

    Should You Pick Boston Scientific Stock Over Its Competitors?

    For questions about this article or underlying research, email help@trefis.com.

71. ❖Nov 3, 2:54 PMnewsvia finnhub

    Should You Buy Baxter Stock For Its Cash?

    For questions about this article or underlying research, email help@trefis.com.

72. ❖Nov 3, 9:41 AMnewsvia finnhub

    Biosensors - Global Strategic Business Report: Secure Share of the $53.7 Billion Market by 2030 as Abbott, Dexcom, Medtronic and Masimo Accelerate Wearable and AI Diagnostics

    Capitalize on demand for wearable, point-of-care biosensors driven by chronic disease monitoring, nanotechnology, personalized medicine, and food and environmental safety.Dublin, Nov. 03, 2026 (GLOBE NEWSWIRE) -- "Biosensors - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global biosensors market was valued at US$35.3 billion in 2024 and is projected to reach US$53.7 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2% during the

73. ❖Nov 3, 8:21 AMnewsvia finnhub

    Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?

    Boston Scientific's steep valuation discount faces a major test as earnings estimates weaken, core franchises lose momentum and key growth catalysts shift to 2028.

74. ❖Nov 3, 7:52 AMnewsvia finnhub

    Spinal cord stimulator lawsuits surge: what is going wrong?

    Despite FDA approval and strong efficacy data, the leading SCS manufacturers are currently all facing personal injury lawsuits.

75. ❖Nov 3, 7:41 AMnewsvia finnhub

    Why Did Boston Scientific Stock Jump?

    For questions about this article or underlying research, email help@trefis.com.

76. ❖Nov 3, 7:30 AMnewsvia finnhub

    BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

    PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (A

77. ❖Nov 3, 7:25 AMnewsvia finnhub

    Abbott’s Amulet 360 demonstrates strong one-year outcomes in AFib patients

    By closing off the left atrial appendage (LAA), Amulet 360 is designed to reduce stroke risk in AFib patients unsuitable for blood-thinning medication regimens.

78. ❖Nov 3, 6:56 AMnewsvia finnhub

    What Are Danaher Investors Betting On?

    For questions about this article or underlying research, email help@trefis.com.

79. ❖Nov 2, 7:17 PMnewsvia finnhub

    Should Retail Leadership Reset Require Action From Marzetti (MZTI) Investors?

    Marzetti recently named Mark Christenson as President of its Retail business and promoted Rene Luichinger to Chief Customer Officer, assigning them responsibility for sales, marketing, innovation and customer strategy across its branded and licensed retail products. The appointments add deep consumer packaged goods and customer development experience from Wingstop, Procter & Gamble and Abbott, which directly targets execution in brand building, volume-led retail growth and retailer...

80. ❖Nov 2, 7:00 PMnewsvia finnhub

    39 New Companies Join the 2026 Fortune Best Companies to Work For Southeast Asia List

    Fortune and Great Place To Work today named the 2026 Fortune Best Companies to Work For Southeast Asia. This year's list has the most change in its line-up so far, with 39 of 100 companies appearing for the first time.

81. ❖Nov 2, 12:48 PMnewsvia finnhub

    Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

    Abbott Laboratories (NYSE:ABT) reported positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego, demonstrating high procedural success and low complication rates in patients with irregular heart rhythms and severely calcified coronary arteries. Strong One-Year Performance For Amulet 360 Data from the pivotal VERITAS study on Monday showed that the investigational Amulet 360 Left Atrial Appendage (LAA)

82. ❖Nov 2, 11:35 AMnewsvia finnhub

    Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion

    Abbott said it is facing pricing pressure and slower growth ahead of a planned coverage expansion for people with Type 2 diabetes. Competitor Dexcom, however, did not experience the same slowdown.

83. ❖Nov 2, 10:48 AMnewsvia finnhub

    Automated and Rapid Microbiological Tests - Global Strategic Business Report: Secure Share of a US$10 Billion Market by 2030 as Abbott, bioMerieux, Bio-Rad, and Becton Dickinson Accelerate

    Boost ROI through AI-enabled rapid testing, point-of-care innovation, clinical and food-safety expansion, and tariff-resilient supply chains.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Automated and Rapid Microbiological Tests - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global automated and rapid microbiological tests market was valued at US$6.7 billion in 2024 and is projected to reach US$10 billion by 2030, expanding at a compound annual growth r

84. ❖Nov 2, 9:00 AMnewsvia finnhub

    Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

    Abbott (NYSE: ABT), the global healthcare leader, announced today one-year results for its investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder from the VERITAS study, which show meaningful closure rates of the left atrial appendage and a low incidence of stroke in people with atrial fibrillation (AFib) not caused by a heart valve issue. The data were presented in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., on Nov. 1

85. ?Oct 21, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] After a clean accumulation run from the $96.69 low on 2026-10-01 through the $104.89 peak on 2026-10-16 — during which up-days consistently printed on modest to moderate volume (7.0M–12.7M) — the last three sessions show a decisive character shift: 2026-10-19 closed down -0.79% on 8.0M, 2026-10-20 closed down -1.55% on 13.8M (1.5× ADV), and today 2026-10-21 closed down -1.89% on 22.8M (a volume z-score of +5.86, 2.5× the 20-day ADV of 9.2M). In the 2-D scatter, the path has pivoted sharply down-and-right — expanding volume coinciding with consecutively lower closes — a textbook SIR distribution signature. All three bearish criteria are met: (1) price was at a multi-week high ($104.89) and today's volume is 2.5× ADV; (2) the most recent 3-session sub-path shows net price decline of −4.38 points on expanding volume (8.0M → 13.8M → 22.8M); (3) the overall 20-day path shows the initial up-and-right drift has reversed into a clear down-and-right drift over the past three sessions, confirming sellers are absorbing the float under price pressure. Risks: This read would be invalidated if ABT recovers above $104.00 on volume returning to or below the 20-day ADV (~9.2M), suggesting today's high-volume down-bar was a one-day event (e.g., a block trade, index rebalance, or earnings-related forced seller) rather than sustained distribution. Additionally, a broader Health Care sector rotation into defensive names — particularly if 2-year Treasury yields reverse from their current 2.1σ elevated level — could re-attract institutional buyers and negate the bearish path signal.

86. ✓Oct 21, 10:25 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    ABT is down ~2.4% on a complex news day: Q3 results were mixed (revenue in-line, some sources calling it a beat on EPS, others a miss), but the dominant driver is the announced spinoff of the Nutrition unit (Similac). The spinoff announcement is creating genuine uncertainty — investors are digesting (1) what RemainCo looks like post-separation, (2) who retains the Similac lawsuit liability (a major overhang given prior infant formula litigation), and (3) whether the strategic rationale justifies the complexity. Headline flow skews negative on the spinoff specifically, with the 4% drop reference in one headline suggesting the initial reaction was even steeper and has partially recovered to -2.4%, which could indicate some stabilization but also residual selling pressure as more investors react through the session. With 320 minutes remaining (well over 5 hours), there is substantial time for the move to continue. Macro context (elevated 2Y rates at 4.77, 2.1σ above trend) is modestly unfavorable for defensive/dividend names like ABT, as higher rates compress valuations on yield-oriented stocks and reduce the appeal of the dividend safety narrative highlighted in some headlines. The broader market appears to be higher (tech-led), which creates a mild headwind for continuation of ABT's decline via rotation effects, but sector divergence on earnings/corporate action days is common. No strong reversal signal present — the stock is not recovering sharply into a gap fill. Lean toward continuation of downside pressure, probability set at 0.62.

87. ▢Oct 20, 8:00 PMjournal

    Agent 7 — Day Trader opened short 29 @ $99.99

88. ▣Oct 20, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed short 29 @ $100.09 (-$2.90)

    EOD forced close — day trader never carries overnight

89. ?Oct 15, 3:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is up 1.87% today, a meaningful move, but with only 10 minutes remaining until the forced 3:45 PM ET close, there is virtually no runway left for continuation. Even a strong setup with clear momentum would be difficult to act on profitably in this window given the fixed profit target of +3% and the time constraint. The macro context (elevated mortgage rates) is not directly relevant to ABT as a medical device/healthcare company. The available headlines are generic and provide no ABT-specific catalyst to sustain buying pressure. With this little time remaining, the dominant risk is mean reversion or simple flatness into the close rather than a push higher. Probability is set below 0.5 to reflect the near-zero time value of continuing the position.

90. !Oct 15, 3:35 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    ABT is up 1.87% today, a meaningful move, but with only 10 minutes remaining until the forced 3:45 PM ET close, there is virtually no runway left for continuation. Even a strong setup with clear momentum would be difficult to act on profitably in this window given the fixed profit target of +3% and the time constraint. The macro context (elevated mortgage rates) is not directly relevant to ABT as a medical device/healthcare company. The available headlines are generic and provide no ABT-specific catalyst to sustain buying pressure. With this little time remaining, the dominant risk is mean reversion or simple flatness into the close rather than a push higher. Probability is set below 0.5 to reflect the near-zero time value of continuing the position.

91. ?Oct 13, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

92. !Oct 13, 1:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

93. ?Oct 13, 12:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

94. !Oct 13, 12:21 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

95. ?Oct 13, 11:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

96. !Oct 13, 11:20 AMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

97. ?Oct 13, 10:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

98. !Oct 13, 10:20 AMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

99. ?Oct 13, 7:00 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

100. !Oct 13, 7:00 AMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

101. ?Oct 12, 4:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

102. !Oct 12, 4:20 PMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

103. ?Oct 12, 3:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

104. !Oct 12, 3:20 PMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

105. ?Oct 12, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

106. !Oct 12, 2:20 PMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

107. ?Oct 12, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

108. !Oct 12, 1:20 PMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

109. ?Oct 12, 12:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

110. !Oct 12, 12:20 PMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

111. ?Oct 12, 11:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

112. !Oct 12, 11:20 AMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

113. ?Oct 12, 10:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

114. !Oct 12, 10:20 AMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

115. ?Oct 12, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

116. !Oct 12, 7:00 AMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

117. ?Oct 9, 4:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

118. !Oct 9, 4:21 PMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

119. ?Oct 9, 3:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

120. !Oct 9, 3:21 PMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

121. ?Oct 9, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

122. !Oct 9, 2:20 PMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

123. ?Oct 9, 1:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

124. !Oct 9, 1:21 PMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

125. ?Oct 9, 12:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

126. !Oct 9, 12:20 PMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

127. ?Oct 9, 11:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

128. !Oct 9, 11:20 AMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

129. ?Oct 9, 10:25 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     ABT is up 1.65% today, a modest but meaningful move suggesting real buying interest. No headlines are available to explain the move, but absence of news is not disqualifying — institutional flow or sector rotation could be driving it. With 320 minutes remaining (a full trading day essentially still ahead), there is ample time for continuation if momentum holds. The macro context (elevated mortgage rates at 3.8σ above trend) is a headwind for homebuilders, REITs, and banks, but ABT is a healthcare/medtech name with minimal direct exposure to mortgage rates — this macro factor is largely neutral for ABT. The 1.65% move is real but not outsized enough to suggest an exhaustion spike or climactic buying. Without reversal signals, fade patterns, or sector-specific headwinds, the base case is mild continuation. Probability is set modestly above 0.5 reflecting ordinary momentum with no strong catalysts in either direction.

130. !Oct 9, 10:25 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     ABT is up 1.65% today, a modest but meaningful move suggesting real buying interest. No headlines are available to explain the move, but absence of news is not disqualifying — institutional flow or sector rotation could be driving it. With 320 minutes remaining (a full trading day essentially still ahead), there is ample time for continuation if momentum holds. The macro context (elevated mortgage rates at 3.8σ above trend) is a headwind for homebuilders, REITs, and banks, but ABT is a healthcare/medtech name with minimal direct exposure to mortgage rates — this macro factor is largely neutral for ABT. The 1.65% move is real but not outsized enough to suggest an exhaustion spike or climactic buying. Without reversal signals, fade patterns, or sector-specific headwinds, the base case is mild continuation. Probability is set modestly above 0.5 reflecting ordinary momentum with no strong catalysts in either direction.

131. ?Oct 9, 10:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

132. !Oct 9, 10:20 AMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

133. ?Oct 9, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

134. !Oct 9, 7:00 AMsignalseverity 0.14

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

135. ?Oct 8, 4:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

136. !Oct 8, 4:20 PMsignalseverity 0.14

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

137. ?Oct 8, 3:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

138. !Oct 8, 3:21 PMsignalseverity 0.14

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

139. ?Oct 8, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

140. !Oct 8, 2:20 PMsignalseverity 0.14

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

141. ?Oct 8, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

142. ?Oct 8, 12:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

143. ?Oct 8, 11:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

144. ?Oct 8, 10:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

145. ?Oct 8, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

146. ?Oct 7, 4:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

147. ?Oct 7, 3:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

148. ?Oct 7, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

149. ?Oct 7, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

150. ?Oct 7, 12:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

151. ?Oct 7, 11:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

152. ?Oct 7, 10:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

153. ?Oct 7, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

154. ?Oct 6, 4:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

155. ?Oct 6, 3:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

156. ?Oct 6, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

157. ?Oct 6, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

158. ▢Oct 4, 8:00 PMjournal

     Agent 7 — Day Trader opened long 29 @ $99.66

159. ▣Oct 4, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 29 @ $100.45 (+$22.91)

     EOD forced close — day trader never carries overnight

160. ▣Aug 23, 8:00 PMjournaltime_stop

     Agent 8 — Dip Buyer (Peer-Aware) closed long 13 @ $116.81 (+$378.16)

     Time stop: held 97 ≥ 90 days

161. ▣Jul 26, 8:00 PMjournaltarget

     Agent 8 — Dip Buyer (Peer-Aware) closed long 12 @ $104.58 (+$202.31)

     Staged exit (1/2.0): close $104.58 ≥ target $103.84. Selling 12/25 sh, trailing remainder.

162. ▢Jul 16, 8:00 PMjournal

     Agent 7 — Day Trader opened long 29 @ $101.37

163. ▣Jul 16, 8:00 PMjournalstop

     Agent 7 — Day Trader closed long 29 @ $99.78 (-$46.11)

     Long stop: close $99.78 ≤ stop $99.85

164. ▣Jun 29, 8:00 PMjournalstop

     options_momentum closed long 100 @ $2.91 (-$83.69)

     Stop: premium $2.91 ≤ trailing floor $3.09 (peak $4.13 × 0.75)

165. ▢Jun 24, 8:00 PMjournal

     options_momentum opened long 100 @ $3.75

166. ▣Jun 9, 8:00 PMjournalstop

     options_momentum closed long 200 @ $2.68 (-$160.47)

     Stop: premium $2.68 ≤ trailing floor $2.69 (peak $3.58 × 0.75)

167. ▢Jun 3, 8:00 PMjournal

     options_momentum opened long 200 @ $3.48

168. ▢Jun 1, 8:00 PMjournal

     Agent 7 — Day Trader opened long 17 @ $87.78

169. ▣Jun 1, 8:00 PMjournalstop

     Agent 7 — Day Trader closed long 17 @ $86.38 (-$23.80)

     Long stop: close $86.38 ≤ stop $86.46

170. ▣May 25, 8:00 PMjournalmanual

     options_momentum closed long 200 @ $2.32 (-$88.27)

     Stop: premium $1.99 ≤ trailing floor $2.08 (peak $2.77 × 0.75)

171. ▢May 19, 8:00 PMjournal

     options_momentum opened long 200 @ $2.76

172. ▢May 18, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 25 @ $84.86

173. ▣May 18, 8:00 PMjournalbank_funding

     Agent 5 — Dip Buyer (Evolving) closed long 25 @ $89.06 (+$105.00)

     Backfill 2026-05-19: closed at current mark to fund initial BANK sweep (highest unrealized P&L first; brings working equity to starting capital).

174. ▢May 18, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 12 @ $87.72

175. ▢May 18, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 13 @ $87.72